MeiraGTx Holdings plc, a clinical-stage gene therapy company, focusing on developing treatments for patients living with serious diseases. The company develops various therapies for ocular diseases, including rare inherited blindness, as well as Xerostomia following radiation treatment for head and neck cancers; neurodegenerative diseases, such as amyothrophic lateral sclerosis; and Parkinson's diseases. Its programs in clinical development include Phase 1/2 clinical stage programs in Achromatopsia, X-Linked Retinitis Pigmentosa, RPE65-deficiency, and radiation-induced Xerostomia, as well as Parkinson's program. The company also focuses on initiating a clinical program in xerostomia related to Sjogren's syndrome and have preclinical programs in neurodegenerative diseases. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. to develop regulatable gene therapy treatment using the company's proprietary riboswitch technology. The company was founded in 2015 and is headquartered in New York, New York.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone646-490-2965
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees68
Next Earnings Date6/25/2019 (Estimated)
OptionableNot Optionable
MeiraGTx (NASDAQ:MGTX) Frequently Asked Questions
What is MeiraGTx's stock symbol?
MeiraGTx trades on the NASDAQ under the ticker symbol "MGTX."
How were MeiraGTx's earnings last quarter?
MeiraGTx Holdings PLC (NASDAQ:MGTX) issued its earnings results on Tuesday, March, 26th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.63) by $0.05. View MeiraGTx's Earnings History.
When is MeiraGTx's next earnings date?
What price target have analysts set for MGTX?
4 analysts have issued 12-month price targets for MeiraGTx's shares. Their predictions range from $20.00 to $40.00. On average, they expect MeiraGTx's share price to reach $27.00 in the next year. This suggests a possible upside of 46.3% from the stock's current price. View Analyst Price Targets for MeiraGTx.
What is the consensus analysts' recommendation for MeiraGTx?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for MeiraGTx in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for MeiraGTx.
What are Wall Street analysts saying about MeiraGTx stock?
Here are some recent quotes from research analysts about MeiraGTx stock:
- 1. According to Zacks Investment Research, "MeiraGTx Holdings plc focuses on operating as a holding company for MeiraGTx Limited which operates as a clinical stage gene therapy company. It develops novel gene therapy treatments for inherited and acquired disorders. The company's product pipeline consists of AAV-CNGB3, AAV-CNGA3, AAV-RPE65, AAV-RPGR, AAV-AQP1, AAV-AQP1 and AAV-UPF1 which are in clinical stage. MeiraGTx Holdings plc is based in New York. " (3/30/2019)
- 2. Chardan Capital analysts commented, "We note this is Meira’s 2nd collaboration with Janssen, the 1st of which was announced on 16 October 2018, and covers Meira’s riboswitch technology, which is particularly relevant for mass market indications." (1/31/2019)
Has MeiraGTx been receiving favorable news coverage?
Media coverage about MGTX stock has trended somewhat positive recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. MeiraGTx earned a daily sentiment score of 1.7 on InfoTrie's scale. They also gave news articles about the company a news buzz of 5.0 out of 10, indicating that recent press coverage is somewhat likely to have an impact on the stock's share price in the near term.
Who are some of MeiraGTx's key competitors?
Some companies that are related to MeiraGTx include Halozyme Therapeutics (HALO), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP), Regenxbio (RGNX), Aerie Pharmaceuticals (AERI), Audentes Therapeutics (BOLD), Alector (ALEC), Orchard Therapeutics (ORTX), Atara Biotherapeutics (ATRA), Momenta Pharmaceuticals (MNTA), Rubius Therapeutics (RUBY), Iovance Biotherapeutics (IOVA), Editas Medicine (EDIT) and Sangamo Therapeutics (SGMO).
What other stocks do shareholders of MeiraGTx own?
Who are MeiraGTx's key executives?
MeiraGTx's management team includes the folowing people:
- Dr. Alexandria Forbes, CEO, Pres & Director (Age 54)
- Mr. Richard Brian Giroux, Chief Operating Officer (Age 46)
- Dr. Stuart Naylor Ph.D., Chief Devel. Officer & Director (Age 56)
- Ms. Katherine Edna Breedis C.F.A., CFA, CMT, Chief Financial Officer
- Mr. Micah Zajic, VP of Corp. Devel.
When did MeiraGTx IPO?
(MGTX) raised $75 million in an IPO on Friday, June 8th 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Barclays and Evercore ISI served as the underwriters for the IPO and Chardan was co-manager.
Who are MeiraGTx's major shareholders?
Which institutional investors are buying MeiraGTx stock?
How do I buy shares of MeiraGTx?
Shares of MGTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is MeiraGTx's stock price today?
One share of MGTX stock can currently be purchased for approximately $18.45.
How big of a company is MeiraGTx?
MeiraGTx has a market capitalization of $612.24 million. The company earns $-82,870,000.00 in net income (profit) each year or ($4.39) on an earnings per share basis. MeiraGTx employs 68 workers across the globe.
What is MeiraGTx's official website?
How can I contact MeiraGTx?
MeiraGTx's mailing address is 430 EAST 29TH STREET 10TH FLOOR, NEW YORK NY, 10016. The company can be reached via phone at 646-490-2965 or via email at [email protected]
MarketBeat Community Rating for MeiraGTx (NASDAQ MGTX)
MarketBeat's community ratings are surveys of what our community members think about MeiraGTx and other stocks. Vote "Outperform" if you believe MGTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MGTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
